1392275-56-7
- Product Name：Tenofovir Alafenamide Fumarate
- Molecular Formula：2(C21H29N6O5P).C4H4O4
- Purity：99%
- Molecular Weight：592.546
Product Details:
CasNo： 1392275-56-7
Molecular Formula： 2(C21H29N6O5P).C4H4O4
Buy High Grade Top Purity Tenofovir Alafenamide Fumarate 1392275-56-7 Fast Delivery
- Molecular Formula:C4H4O4*C21H29N6O5P
- Molecular Weight:592.546
- PSA：381.18000
- LogP:7.60180
Tenofovir Alafenamide Fumarate(Cas 1392275-56-7) Usage
|
Description |
Tenofovir Alafenamide Fumarate (TAF) is a phosphonamide prodrug of tenofovir, which is hydrolyzed to tenofovir in hepatocytes. It is a lipophilic prodrug that is preferentially metabolized in lymphatic tissue, leading to high concentrations of tenofovir and its active metabolite inside cells that replicate HIV or HBV. TAF is absorbed more quickly than Tenofovir Disoproxil Fumarate (TDF) and produces higher levels of the active drug, tenofovir diphosphate, in cells. |
| Uses | Tenofovir Alafenamide Fumarate is indicated for the treatment of chronic HBV infection in patients with compensated liver disease. TAF has become a key component in multiple combination products for the treatment of HIV. It offers an effective and convenient option for patients with HBV infection, particularly those with compensated liver disease. |
1392275-56-7 Relevant articles
Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340
Chapman,Kernan,Prisbe,Rohloff,Sparacino,Terhorst,Yu
, p. 621 - 628 (2001)
The practical synthesis of a mixed pheno...
Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy A Randomized Phase 2 Study
Sax, Paul E. MD*; Zolopa, Andrew MD†; Brar, Indira MD‡; Elion, Richard MD§; Ortiz, Roberto MD‖; Post, Frank MD, PhD, FCP (SA)¶; Wang, Hui PhD#; Callebaut, Christian PhD#; Martin, Hal MD, MPH#; Fordyce, Marshall W. MD#; McCallister, Scott MD#
, JAIDS Journal of Acquired Immune Deficiency Syndromes 67(1):p 52-58, September 1, 2014.
Antiretroviral naive adults with HIV-1 RNA ≥5000 copies per milliliter and a CD4 count ≥50 cells per microliter were randomized 2:1 to receive an STR of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF), plus placebo for 48 weeks.
Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
Andrew Hill 1, Sophie L. Hughes 2, Dzintars Gotham 2, Anton L. Pozniak 3
, Journal of Virus Eradication Volume 4, Issue 2, April 2018, Pages 72-79
The test for differences by boosting revealed substantial heterogeneity between boosted and unboosted subgroups for study discontinuations due to renal toxicity through week 48 (I2=73%). The risk of discontinuation for renal adverse events was 1% lower for boosted TAF than boosted TDF (95% CI -1% to 0%, P=0.002). However, there was no difference in the risk of discontinuation for renal adverse events for unboosted TAF and unboosted TDF (difference=0%, 95% CI 0%).
1392275-56-7 Upstream products
-
110-17-8
(2E)-but-2-enedioic acid
-
383365-04-6
N-[(R)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphonyl]-L-alanine-1-methylethyl ester
-
39825-33-7
isopropyl L-alanine
-
147127-20-6
tenofovir
1392275-56-7 Downstream products
-
379270-37-8
(S)-isopropyl-2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate
Relevant Products
-
Levofloxacin HemihydrateCAS：138199-71-0
-
GemfibrozilCAS：25812-30-0
-
Vinorelbine TartrateCAS：125317-39-7
